Resorcinol

The dosage of Resorcinol is highly individualized based on the condition being treated and the specific formulation used. For general dermatological applications:

• Acne Vulgaris (OTC Preparations): Apply a thin layer of 2% Resorcinol (often with sulfur) to the affected areas one to three times daily. It is recommended to start with a single daily application to assess skin tolerance before increasing the frequency.
• Seborrheic Dermatitis: Apply the medicated lotion or cream to the affected areas of the scalp or skin twice daily.
• Calluses and Corns: Higher concentrations (up to 10-20%) may be applied specifically to the thickened skin area, usually once or twice daily, under medical supervision.
• Professional Chemical Peels: These are one-time applications performed by a specialist, with frequency determined by the patient's skin response and treatment goals.

Resorcinol should be used with extreme caution in the pediatric population.

• Children under 2 years: Use is generally contraindicated due to the high risk of systemic absorption and methemoglobinemia (a blood disorder where oxygen is not effectively released to tissues).
• Children 2 to 12 years: Use must be directed by a pediatrician. Dosing is typically limited to small areas for short durations. The risk of 'resorcinolism' is significantly higher in children due to their larger surface-area-to-weight ratio.

Renal Impairment

Since Resorcinol metabolites are primarily excreted through the kidneys, patients with significant renal impairment should use topical Resorcinol with caution. While systemic levels from small-area applications are low, extensive use could lead to metabolite accumulation.

Hepatic Impairment

Metabolism occurs via hepatic conjugation. Those with severe liver disease may have a reduced capacity to clear absorbed Resorcinol, increasing the risk of systemic toxicity. Monitoring for signs of resorcinolism is advised.

Elderly Patients

Elderly patients often have thinner skin (atrophic skin), which may increase the rate of percutaneous absorption. It is recommended to use the lowest effective concentration and monitor for any systemic effects, particularly thyroid function and neurological changes.

Resorcinol is for external use only. Follow these steps for safe application:

1. 1Cleanse the area: Wash the affected skin with a mild cleanser and pat dry before application.
2. 2Apply a thin film: Use only enough medication to cover the affected area. Do not 'slather' the product on.
3. 3Avoid sensitive areas: Keep the medication away from the eyes, nostrils, mouth, and any mucous membranes. If contact occurs, rinse thoroughly with water.
4. 4Wash hands: Always wash your hands immediately after applying Resorcinol to prevent accidental transfer to other areas.
5. 5Storage: Store at room temperature (15°C to 30°C / 59°F to 86°F) in a tightly closed container, away from direct sunlight and moisture. Resorcinol can darken over time when exposed to light and air; while slight darkening may not affect potency, significant discoloration suggests the product should be discarded.

If you miss a dose, apply it as soon as you remember. However, if it is almost time for your next application, skip the missed dose and resume your regular schedule. Do not double the amount applied to 'catch up.'

Systemic overdose from topical Resorcinol is a medical emergency. Signs of acute toxicity include:

• Severe dizziness or fainting
• Rapid or irregular heartbeat (tachycardia)
• Shortness of breath or bluish skin (cyanosis, indicating methemoglobinemia)
• Profuse sweating and tremors
• Seizures or loss of consciousness

In case of suspected overdose or accidental ingestion, contact a Poison Control Center or seek emergency medical attention immediately. Treatment is supportive, focusing on clearing the airway and, in cases of methemoglobinemia, administering methylene blue.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or apply to large areas of the body without medical guidance.

Most patients using Resorcinol for the first time will experience some degree of local skin reaction. These are generally mild and expected as part of the keratolytic (peeling) process:

• Redness (Erythema): The treated area may appear pink or red shortly after application.
• Peeling and Scaling: As the medication breaks down the outer skin layer, visible flaking is common.
• Mild Burning or Stinging: A transient sensation of warmth or stinging may occur upon application, typically lasting only a few minutes.
• Dryness: Resorcinol can significantly reduce skin oils, leading to a feeling of tightness.

• Contact Dermatitis: Some individuals may develop an itchy, red rash that extends beyond the application site, indicating a localized allergic reaction.
• Skin Discoloration: Resorcinol may cause temporary darkening or brownish staining of the skin, particularly in individuals with darker skin tones. It can also stain light-colored hair or fabrics.
• Increased Sensitivity to Sunlight: The removal of the outer skin layer makes the underlying skin more prone to sunburn.

• Severe Edema: Swelling of the treated area.
• Urticaria: Hives or widespread itching.
• Hypopigmentation: Permanent or long-lasting lightening of the skin in the treated area.

> Warning: Stop using Resorcinol and call your doctor immediately if you experience any of the following symptoms, as they may indicate systemic toxicity (resorcinolism):

• Methemoglobinemia Symptoms: If your skin, lips, or fingernails turn blue or gray, or if you experience extreme fatigue, headache, and shortness of breath. This occurs when Resorcinol interferes with the blood's ability to carry oxygen.
• Thyroid Dysfunction: Resorcinol is a known goitrogen. Signs include unexplained weight gain, extreme cold sensitivity, swelling in the neck (goiter), or a slow heart rate. This is usually seen with prolonged use over large areas.
• Central Nervous System Effects: Dizziness, confusion, ringing in the ears (tinnitus), or involuntary muscle twitching.
• Severe Allergic Reaction (Anaphylaxis): Swelling of the face, tongue, or throat; severe dizziness; or difficulty breathing.

Prolonged use of Resorcinol, especially on large surface areas, can lead to chronic suppression of thyroid peroxidase enzymes, potentially resulting in clinical hypothyroidism. Additionally, chronic irritation can lead to 'lichenification' (thickening and leathery texture) of the skin. There is limited data on the long-term carcinogenic potential in humans, but chronic high-dose exposure in animal models has shown various systemic impacts.

No FDA black box warnings are currently issued for Resorcinol. However, the FDA has issued warnings regarding the use of Resorcinol in infants and the risk of methemoglobinemia, which serves as a de facto critical safety contraindication for the pediatric population.

Report any unusual symptoms or persistent irritation to your healthcare provider. Monitoring of thyroid function may be necessary if the drug is used long-term.

Resorcinol is a potent chemical agent that must be handled with care. It is intended solely for topical use on intact skin unless otherwise directed by a physician. Users must be aware that the skin's barrier function is the primary defense against systemic toxicity; therefore, any condition that compromises the skin (wounds, ulcers, severe inflammation) significantly increases the risk of dangerous systemic absorption.

There are no formal FDA black box warnings for Resorcinol at this time. However, clinical guidelines emphasize that it must not be used on large areas of the body or for extended periods without medical supervision due to the risk of thyroid suppression and blood disorders.

• Methemoglobinemia Risk: Resorcinol can induce the formation of methemoglobin, especially in young children or individuals with G6PD deficiency. This prevents red blood cells from releasing oxygen to the body's tissues. If you notice a bluish tint to the skin or lips, seek emergency care.
• Thyroid Suppression: Resorcinol acts as a goitrogen by inhibiting the enzyme thyroid peroxidase. Patients with pre-existing thyroid conditions (hypothyroidism, goiter) should use Resorcinol only under strict medical monitoring.
• Allergic Sensitization: As a 'Standardized Chemical Allergen,' Resorcinol has a high potential to cause sensitization. If you develop an escalating rash or severe itching, you may have developed an allergy to the compound.
• Percutaneous Absorption: The risk of systemic toxicity is directly proportional to the surface area treated. Avoid 'whole-body' applications. Limit use to the smallest area necessary to treat the condition.
• Staining: Resorcinol can stain skin, hair, and clothing. It may turn light-colored hair a reddish or brownish tint. Use caution when applying near the hairline or when wearing expensive garments.

For patients using Resorcinol over large areas or for chronic conditions, healthcare providers may require the following:

• Thyroid Function Tests (TFTs): Monitoring TSH, T3, and T4 levels to ensure the drug is not causing hypothyroidism.
• Complete Blood Count (CBC): To monitor for any signs of blood dyscrasias or methemoglobinemia in high-risk patients.
• Skin Assessment: Regular evaluation by a dermatologist to ensure the skin is not becoming overly thinned or sensitized.

Topical Resorcinol generally does not interfere with the ability to drive or operate machinery. However, if systemic absorption occurs, symptoms like dizziness or confusion could impair these activities. If you feel lightheaded, avoid these tasks and contact your doctor.

There are no direct contraindications between moderate alcohol consumption and topical Resorcinol use. However, alcohol can cause vasodilation (widening of blood vessels), which might theoretically increase skin absorption or exacerbate the redness and flushing associated with Resorcinol application.

Resorcinol does not typically require a tapering period. However, if you have been using it for a long period to treat a condition like psoriasis, stopping suddenly may cause a 'rebound' flare-up of symptoms. Consult your doctor for a discontinuation plan if you have used the product chronically.

> Important: Discuss all your medical conditions, especially thyroid or blood disorders, with your healthcare provider before starting Resorcinol.

While Resorcinol is topical, certain combinations increase the risk of severe skin damage or systemic issues:

• Other Strong Keratolytics (e.g., high-strength Salicylic Acid or Hydroquinone): Using these simultaneously with Resorcinol can lead to excessive skin stripping, severe irritation, and significantly increased systemic absorption of both drugs.
• Abrasive Cleansers or Medicated Soaps: Combining Resorcinol with 'scrubs' or soaps containing benzoyl peroxide or tretinoin without medical guidance can lead to severe chemical burns and skin barrier breakdown.

• Systemic Thyroid Medications (e.g., Levothyroxine): Because Resorcinol can inhibit thyroid function, it may counteract the effects of thyroid hormone replacement therapy. Patients on these medications require frequent TSH monitoring.
• Methemoglobin-Inducing Agents (e.g., Nitrates, Prilocaine, certain Sulfonamides): Using Resorcinol alongside other drugs known to cause methemoglobinemia can have an additive effect, leading to a life-threatening lack of oxygen in the tissues.

• Topical Corticosteroids: While sometimes used together to reduce inflammation, corticosteroids can thin the skin (atrophy), which may increase the absorption of Resorcinol into the bloodstream.
• Tretinoin/Retinoids: These medications increase cell turnover and thin the stratum corneum, which can make the skin much more sensitive to the irritating effects of Resorcinol.

There are no known significant interactions between Resorcinol and specific foods. However, a diet high in goitrogenic foods (like raw kale, broccoli, or cassava) might theoretically exacerbate the thyroid-suppressing effects of absorbed Resorcinol.

• Iodine Supplements: Since Resorcinol interferes with iodine organification in the thyroid, excessive iodine intake might complicate the clinical picture of Resorcinol-induced goiter.
• St. John’s Wort: While primarily a concern for oral drugs, any supplement that increases skin sensitivity to light (photosensitivity) should be used cautiously with Resorcinol.

Resorcinol can interfere with certain laboratory diagnostic tests:

• Urinary Glucose Tests: Resorcinol may cause false-positive results in certain copper reduction tests (e.g., Benedict's solution).
• Thyroid Scans: Absorbed Resorcinol can interfere with radioactive iodine uptake tests, leading to inaccurate assessments of thyroid function.
• Ferric Chloride Test: Resorcinol reacts with ferric chloride to produce a violet color, which may interfere with urine tests for salicylates or other phenols.

For each major interaction, the mechanism involves either pharmacodynamic synergy (increased skin irritation) or systemic biochemical interference (peroxidase inhibition). Management typically involves spacing out applications, reducing concentrations, or choosing alternative therapies.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including other skin care products.

Resorcinol must NEVER be used in the following circumstances:

1. 1Known Hypersensitivity: If you have a documented allergy to Resorcinol or other phenolic compounds (such as phenol or hydroquinone), use is strictly prohibited due to the risk of anaphylaxis or severe contact dermatitis.
2. 2Infants and Neonates: Due to the high risk of methemoglobinemia and the immature metabolic pathways in infants, Resorcinol is absolutely contraindicated in children under 2 years of age.
3. 3Application to Large Areas of Broken Skin: Applying Resorcinol to open wounds, ulcers, or denuded skin (skin where the top layer is missing) is contraindicated because it allows for rapid, potentially lethal systemic absorption.
4. 4Severe Renal Disease: Patients with end-stage renal failure should avoid Resorcinol due to the inability to clear absorbed metabolites.

Conditions requiring a careful risk-benefit analysis by a physician include:

• Pre-existing Hypothyroidism: Because Resorcinol is goitrogenic, it can worsen thyroid deficiency.
• G6PD Deficiency: Individuals with this genetic enzyme deficiency are at a much higher risk of developing hemolytic anemia or methemoglobinemia if Resorcinol is absorbed systemically.
• Pregnancy and Lactation: Use should be restricted to small areas only if the benefit clearly outweighs the potential risk to the fetus or infant.
• Dark Skin Tones: Due to the risk of post-inflammatory hyperpigmentation or temporary staining, Resorcinol should be used with caution and under professional guidance in patients with darker complexions.

Patients who are allergic to the following substances may also react to Resorcinol:

• Hexylresorcinol (found in some throat lozenges)
• Hydroquinone (a skin-lightening agent)
• Pyrocatechol
• Phenylenediamine (found in hair dyes)

> Important: Your healthcare provider will evaluate your complete medical history, including any history of anemia or thyroid issues, before prescribing Resorcinol.

Resorcinol is classified as FDA Pregnancy Category C (under the older system). There are no adequate and well-controlled studies in pregnant women. Animal studies have shown that systemic absorption of phenols can have adverse effects on fetal development.

• First Trimester: Avoid use if possible, as this is the critical period for organogenesis.
• Second and Third Trimesters: Use only on very small, localized areas. Avoid application to the abdomen or breasts.
• Risk: The primary risk is systemic absorption leading to maternal thyroid dysfunction, which can indirectly affect fetal brain development.

It is unknown whether topically applied Resorcinol is excreted in human milk. However, many phenolic compounds do pass into breast milk.

• Precautions: Do not apply Resorcinol to the breast area to prevent the infant from direct ingestion or skin contact during nursing.
• Recommendation: If Resorcinol must be used, apply it to the smallest area possible and monitor the infant for any signs of lethargy or bluish skin tint.

Children are at a significantly higher risk for Resorcinol toxicity.

• Approved Use: Only for children over 2 years old, and only under strict medical supervision.
• Safety: There have been documented cases of death in infants following the application of Resorcinol-containing ointments to large areas of dermatitis.
• Growth Effects: Chronic use could theoretically affect growth if it induces hypothyroidism.

In patients over 65, the skin is often thinner and more permeable.

• Absorption: Increased risk of systemic absorption.
• Renal Function: Natural age-related decline in kidney function may slow the clearance of absorbed Resorcinol.
• Polypharmacy: Elderly patients are more likely to be on medications (like heart medications or blood thinners) that could interact with the systemic effects of Resorcinol.

In patients with a GFR (Glomerular Filtration Rate) below 30 mL/min, the excretion of conjugated Resorcinol is significantly impaired. While topical use on small areas is generally safe, extensive use should be avoided. Dialysis does not effectively clear Resorcinol metabolites.

Patients with Child-Pugh Class B or C hepatic impairment may have difficulty conjugating Resorcinol. This can lead to higher levels of 'free' Resorcinol in the blood, which is more toxic than its conjugated form. Use with extreme caution and monitor for signs of CNS depression or tachycardia.

> Important: Special populations require individualized medical assessment to ensure that the topical benefits of Resorcinol do not lead to systemic complications.

Resorcinol acts primarily as a keratolytic agent. At the molecular level, it interacts with the keratinocytes (skin cells) in the stratum corneum. It functions by reducing the thiol group content in the skin and disrupting hydrogen bonding between keratin molecules. This results in the softening of the cornified layer of the epidermis, facilitating its shedding.

Additionally, Resorcinol exhibits mild antiseptic properties by denaturing bacterial and fungal proteins. Its provided MoA as a Cyclooxygenase Inhibitor suggests it may interfere with the arachidonic acid cascade, providing a secondary anti-inflammatory effect. Its role as an Estrogen Receptor Agonist is likely due to its structural similarity to certain estrogenic phenols, allowing it to bind to estrogen receptors, though with much lower affinity than endogenous estradiol.

• Dose-Response: Higher concentrations (up to 50%) produce deep chemical peeling, while lower concentrations (2-5%) provide mild desquamation.
• Onset of Action: Keratolytic effects typically begin within 24 to 48 hours of consistent application.
• Duration: The effect lasts as long as the medication is applied; skin cell turnover returns to baseline within 1-2 weeks after discontinuation.
• Tolerance: Tachyphylaxis (diminishing response) is not commonly reported with Resorcinol, though the skin may become 'hardened' or sensitized over time.

| Parameter | Value |

|---|---|

| Bioavailability | 1% - 10% (Topical, depends on skin integrity) |

| Protein Binding | Minimal |

| Half-life | 1.5 - 3 hours (Systemic) |

| Tmax | 1 - 2 hours after topical application |

| Metabolism | Hepatic (Glucuronidation and Sulfation) |

| Excretion | Renal (>90% as conjugates) |

• Molecular Formula: C6H6O2
• Molecular Weight: 110.11 g/mol
• Solubility: Highly soluble in water, alcohol, and ether.
• Structure: A benzene ring with two hydroxyl groups at the 1 and 3 positions (meta-position).

Resorcinol is classified as a keratolytic and antiseptic. It is related to other phenols like salicylic acid and hydroquinone but has a distinct profile due to its specific dihydroxybenzene structure. It is often grouped with sulfur in 'Acne Therapeutic Combinations.'